✨ Free AI Report
Unity Biotechnology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Unity Biotechnology, Inc.
Company Research

Unity Biotechnology, Inc.: Business Overview, Financials & Competitive Analysis

Unity Biotechnology was a biotechnology company that developed therapeutics to slow, halt, or reverse diseases of aging, with a focus on senolytic medicines that clear senescent cells from the human body. The company ...

Analyst-debate audio for Unity Biotechnology, Inc.

AskCyborg analysts argue the bull and bear cases for Unity Biotechnology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

A pioneer in senolytic therapeutics that ultimately could not overcome clinical and commercial hurdles before shutting down...

Read the full analyst-debate transcript →
Industry Biotechnology - Senolytic Therapeutics / Aging/Longevity
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Unity Biotechnology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Unity Biotechnology, Inc. Overview

Pro stress-test →

Unity Biotechnology was a biotechnology company that developed therapeutics to slow, halt, or reverse diseases of aging, with a focus on senolytic medicines that clear senescent cells from the human body. The company operated until 2025 and had a pipeline targeting ophthalmology, pulmonary, and age-related diseases.

Strategic Profile

Pro stress-test →

The company pioneered the senolytic drug class, positioning itself in the emerging longevity/aging-biology space with backing from notable investors including Jeff Bezos and Peter Thiel. Its lead candidate UBX1325 advanced through Phase 2 clinical trials for age-related eye diseases, demonstrating vision gains comparable to standard treatments.

Competitive Landscape

Pro stress-test →

Competitors in the aging/senolytic space included traditional ophthalmology players like Regeneron (aflibercept), AbbVie in age-related disease spaces, and emerging longevity biotech companies. Unity's differentiation was its senolytic mechanism targeting senescent cell clearance, but the company could not sustain commercial viability.

Industry Context

Unity Biotechnology, Inc. operates in Biotechnology - Senolytic Therapeutics / Aging/Longevity.

Key facts

Founded: 2009 · Headquarters: South San Francisco, California

What the analysts stress-tested

The top findings that survived the multi-agent debate for Unity Biotechnology, Inc..

  • Company ceased operations in 2025 despite having multiple clinical-stage candidates in development
  • Lead asset UBX1325 showed non-inferiority to aflibercept in Phase 2 for diabetic macular edema (March 2025)
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2025UBX1325 demonstrated non-inferiority to aflibercept in difficult-to-treat patient population
  • May 2025Final announcements from company before operational wind-down
  • +1 moreTrack every material event for Unity Biotechnology, Inc. as it happens. Explore monitoring →
Get alerted when Unity Biotechnology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

afliberceptAnti-VEGF therapy used in diabetic macular edema and age-related macular degeneration→Age-related disease therapiesCompetitors in neurology, pulmonary, and ophthalmology domains for aging-related indications→

Compare Unity Biotechnology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Unity Biotechnology, Inc. operates in Biotechnology - Senolytic Therapeutics / Aging/Longevity. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Senolytic Therapeutics / Aging/Longevity research →
NEW · MCP server

Ask your AI assistant about Unity Biotechnology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Unity Biotechnology, Inc. and its top competitor on Cyborg Score”
“What did Unity Biotechnology, Inc. do this quarter?”
“Is Unity Biotechnology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Unity Biotechnology, Inc. do?+
Unity Biotechnology was a biotechnology company that developed therapeutics to slow, halt, or reverse diseases of aging, with a focus on senolytic medicines that clear senescent cells from the human body. The company ...
What is Unity Biotechnology, Inc.'s Cyborg Score?+
Unity Biotechnology, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Unity Biotechnology, Inc.'s main competitors?+
Named competitors include aflibercept, Age-related disease therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Unity Biotechnology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Unity Biotechnology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Unity Biotechnology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Senolytic Therapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

3Unity Biotechnology, Inc.